COVID-19 Ibuprofen Fears Hit Advil Sales In GSK’s Q2
Executive Summary
Reports that ibuprofen could worsen COVID-19 in the early months of the pandemic hit sales of GSK's leading Advil brand, contributing to a drop in pro-forma Consumer Healthcare turnover in the second quarter of 2020.
You may also be interested in...
GSK Rides E-Commerce Wave In Choppy COVID Waters
GSK saw investments in e-commerce paying off in 2020 as the firm was able to meet increased demand for consumer health products during the pandemic while many shoppers remained indoors.
UK Says Still No Evidence Vitamin D Prevents Or Treats COVID-19
Yet another rapid review by the UK's NICE finds insufficient evidence to support taking vitamin D to prevent or treat COVID-19. Nevertheless, the UK government is handing out free vitamin D supplements to clinically vulnerable groups in England from Janurary.
GSK Sells Lesser Consumer Brands With Little Fanfare As Part Of Major Plan For Global Lead
Deal with Foundation Consumer Brands marks GSK’s latest sale of OTC and nutritional brands that aren’t strong enough revenue drivers to remain part of its consumer health JV with Pfizer. GSK has controlled the brands it’s divesting for less than a year.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: